Literature DB >> 16569882

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Barbara J Hoeben1, David S Burgess, Jason T McConville, Laura K Najvar, Robert L Talbert, Jay I Peters, Nathan P Wiederhold, Bradi L Frei, John R Graybill, Rosie Bocanegra, Kirk A Overhoff, Prapasri Sinswat, Keith P Johnston, Robert O Williams.   

Abstract

Aerosolized evaporative precipitation into aqueous solution and spray freezing into liquid nanostructured formulations of itraconazole as prophylaxis significantly improved survival relative to commercial itraconazole oral solution and the control in a murine model of invasive pulmonary aspergillosis. Aerosolized administration of nanostructured formulations also achieved high lung tissue concentrations while limiting systemic exposure.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569882      PMCID： PMC1426984          DOI： 10.1128/AAC.50.4.1552-1554.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  A novel particle engineering technology: spray-freezing into liquid.

Authors:  True L Rogers; Jiahui Hu; Zhongshui Yu; Keith P Johnston; Robert O Williams
Journal:  Int J Pharm       Date:  2002-08-21       Impact factor: 5.875

2.  Enhanced drug dissolution using evaporative precipitation into aqueous solution.

Authors:  Marazban Sarkari; Judith Brown; Xiaoxia Chen; Steve Swinnea; Robert O Williams; Keith P Johnston
Journal:  Int J Pharm       Date:  2002-08-28       Impact factor: 5.875

3.  Device for inhalation exposure of animals to spores.

Authors:  W R PIGGOTT; C W EMMONS
Journal:  Proc Soc Exp Biol Med       Date:  1960-04

Review 4.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

5.  In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.

Authors:  Russell E Lewis; Nathan P Wiederhold; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats.

Authors:  E J Ruijgrok; A G Vulto; E W Van Etten
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

7.  Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum.

Authors:  P O Gubbins; B J Gurley; J Bowman
Journal:  J Pharm Biomed Anal       Date:  1998-02       Impact factor: 3.935

8.  Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.

Authors:  P J Paterson; S Seaton; H G Prentice; C C Kibbler
Journal:  J Antimicrob Chemother       Date:  2003-09-30       Impact factor: 5.790

9.  Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.

Authors:  Drew J Winston; Richard T Maziarz; Pranatharthi H Chandrasekar; Hillard M Lazarus; Mitchell Goldman; Jeffrey L Blumer; Gerhard J Leitz; Mary C Territo
Journal:  Ann Intern Med       Date:  2003-05-06       Impact factor: 25.391

10.  A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid.

Authors:  True L Rogers; Andrew C Nelsen; Jiahui Hu; Judith N Brown; Marazban Sarkari; Timothy J Young; Keith P Johnston; Robert O Williams
Journal:  Eur J Pharm Biopharm       Date:  2002-11       Impact factor: 5.571
View more
  14 in total

1.  Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile.

Authors:  Wean Sin Cheow; Matthew Wook Chang; Kunn Hadinoto
Journal:  Pharm Res       Date:  2010-04-21       Impact factor: 4.200

2.  New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

Review 3.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

4.  Inhaled antimicrobial therapies for respiratory infections.

Authors:  Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

5.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

6.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

7.  Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

Authors:  Zaid Al-Nakeeb; Ajay Sudan; Adam R Jeans; Lea Gregson; Joanne Goodwin; Peter A Warn; Timothy W Felton; Susan J Howard; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

8.  In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery.

Authors:  A Woods; A Patel; D Spina; Y Riffo-Vasquez; A Babin-Morgan; R T M de Rosales; K Sunassee; S Clark; H Collins; K Bruce; L A Dailey; B Forbes
Journal:  J Control Release       Date:  2015-05-14       Impact factor: 9.776

Review 9.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

10.  In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection.

Authors:  Thomas Colley; Alexandre Alanio; Steven L Kelly; Gurpreet Sehra; Yasuo Kizawa; Andrew G S Warrilow; Josie E Parker; Diane E Kelly; Genki Kimura; Lauren Anderson-Dring; Takahiro Nakaoki; Mihiro Sunose; Stuart Onions; Damien Crepin; Franz Lagasse; Matthew Crittall; Jonathan Shannon; Michael Cooke; Stéphane Bretagne; John King-Underwood; John Murray; Kazuhiro Ito; Pete Strong; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.